BRAF and neoplasm: A phase Ib/II study (NCT01543698) evaluated triple combination therapy with encorafenib, binimetinib and ribociclib in patients with BRAF V600 mutant melanoma naive to prior BRAF inhibitor treatment and with high tumor burden.